Risk of suicidality during smoking cessation treatment is an important, but often overlooked, aspect of nicotine addiction research and treatment. We explore the relationship between smoking cessation interventions and suicidality and explore common treatments, their associated risks, and effectiveness in promoting smoking reduction and abstinence. Although active smokers have been reported to have twofold to threefold increased risk of suicidality when compared to nonsmokers,1–4 research regarding the safest way to stop smoking does not always provide clear guidelines for practitioners wishing to advise their patients regarding smoking cessation strategies. In this article, we review pharmacological and cognitive behavioral therapy (CBT) options that are available for people seeking to quit smoking, focusing on the relationship between the ability of these therapies to reduce smoking behavior and promote abstinence and suicidality risks as assessed by reported suicidality on validated measures, reports of suicidal ideation, behaviors, actual attempts, or completed suicides. Pharmacotherapies such as varenicline, bupropion, and nicotine replacement, and CBTs, including contextual CBT interventions, have been found to help reduce smoking rates and promote and maintain abstinence. Suicidality risks, while present when trying to quit smoking, do not appear to demonstrate a consistent or significant rise associated with use of any particular smoking cessation pharmacotherapy or CBT/contextual CBT intervention reviewed.

No abstract

Over the past few decades, there have been minimal advances in effective new behavioral or psychotherapeutic interventions for people living with autoimmune diseases such as systematic lupus erythematosus. This is problematic due to the severe, debilitating and potentially lifethreatening nature of these diseases. Mindfulness based interventions, such as Mindfulness Based Stress Reduction, have demonstrated effectiveness in a wide range of patient populations and we hypothesize such treatment would also benefit patients with autoimmune disorders and related symptoms. We further hypothesize that these therapies will work by impacting physiological mechanisms, such as inflammatory markers, associated with such disease symptoms. We present our findings below.

No abstract

No abstract